Patient and community preferences for treatments and health states in multiple sclerosis
暂无分享,去创建一个
Amit Bar-Or | Milton C Weinstein | Karen M Kuntz | Lisa A Prosser | M. Weinstein | A. Bar-Or | L. Prosser | K. Kuntz
[1] S. Steinmetz,et al. Notes from the insurance underground: how the chronically ill cope. , 1994, Journal of health politics, policy and law.
[2] M. Weinstein,et al. Preference-based measures in economic evaluation in health care. , 2000, Annual review of public health.
[3] Carolyn E. Schwartz,et al. Reliability and validity of two self-report measures of impairment and disability for MS , 1999, Neurology.
[4] G W Torrance,et al. Multi-attribute health status classification systems. Health Utilities Index. , 1995, PharmacoEconomics.
[5] G. Torrance,et al. Cost and health related quality of life consequences of multiple sclerosis , 2000, Multiple sclerosis.
[6] D. Goodin,et al. Side-effect profile of interferon beta 1-B , 1995, Journal of Neuroimmunology.
[7] G. W. Ellison,et al. A health-related quality of life measure for multiple sclerosis , 1995, Quality of Life Research.
[8] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[9] W. O'Fallon,et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota , 1990, Neurology.
[10] G. Karabatsos,et al. Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument , 1996, Neurology.
[11] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[12] D. Goodin. Survey of multiple sclerosis in Northern California , 1999 .
[13] J. Law,et al. Screening for speech and language delay: a systematic review of the literature. , 1998, Health technology assessment.
[14] S. Neilson,et al. Static and dynamic models of interdisease competition: Past and projected mortality from amyotrophic lateral sclerosis and multiple sclerosis , 1993, Mechanisms of Ageing and Development.
[15] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[16] X. Montalban,et al. Interferon-β1b in the treatment of multiple sclerosis , 2005, Expert opinion on pharmacotherapy.
[17] G. Torrance. Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.
[18] A. Jacoby,et al. A cost-utility analysis of interferon beta for multiple sclerosis. , 1998, Health technology assessment.
[19] B. McNeil,et al. Fallacy of the five-year survival in lung cancer. , 1978, The New England journal of medicine.
[20] B. O'brien,et al. Are health states "timeless"? The case of the standard gamble method. , 1999, Journal of clinical epidemiology.
[21] R. Farmer,et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. , 1992, Archives of neurology.
[22] D. Paty,et al. Life expectancy in patients attending multiple sclerosis clinics , 1992, Neurology.
[23] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[24] R. Knobler,et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. , 1993, Journal of interferon research.
[25] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[26] G. Omenn. Public health genetics: an emerging interdisciplinary field for the post-genomic era. , 2000, Annual review of public health.
[27] D. Mohr,et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.
[28] P. Dolan,et al. The time trade-off method: results from a general population study. , 1996, Health economics.
[29] L. Jacobs,et al. A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium , 1999, Multiple sclerosis.